FY2024 EPS Estimates for SI-BONE Lifted by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN) – Equities research analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for SI-BONE in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.65) per share for the year, up from their previous forecast of ($0.69). The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share. Cantor Fitzgerald also issued estimates for SI-BONE’s FY2025 earnings at ($0.19) EPS.

A number of other equities analysts have also recently commented on the company. Truist Financial lifted their price target on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research note on Monday, January 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $23.00.

SI-BONE Trading Down 3.8 %

NASDAQ SIBN opened at $16.64 on Thursday. SI-BONE has a 1-year low of $11.70 and a 1-year high of $21.64. The stock has a 50-day moving average of $13.93 and a 200-day moving average of $14.41. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

Insider Transactions at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 2,439 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the sale, the chief financial officer now owns 194,623 shares in the company, valued at approximately $2,467,819.64. This represents a 1.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,670 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,348 shares of company stock valued at $356,349 in the last quarter. 3.90% of the stock is owned by insiders.

Institutional Trading of SI-BONE

Hedge funds and other institutional investors have recently bought and sold shares of the stock. R Squared Ltd bought a new position in SI-BONE during the fourth quarter valued at $73,000. Harbor Capital Advisors Inc. raised its position in SI-BONE by 35.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock worth $11,791,000 after purchasing an additional 220,555 shares during the period. JPMorgan Chase & Co. lifted its stake in SI-BONE by 14.7% in the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company’s stock worth $2,486,000 after purchasing an additional 22,732 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of SI-BONE by 9.4% during the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after buying an additional 1,745 shares during the period. Finally, Barclays PLC boosted its position in shares of SI-BONE by 190.8% during the third quarter. Barclays PLC now owns 96,623 shares of the company’s stock valued at $1,350,000 after buying an additional 63,402 shares during the period. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.